[go: up one dir, main page]

NO20061239L - Fremgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser - Google Patents

Fremgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser

Info

Publication number
NO20061239L
NO20061239L NO20061239A NO20061239A NO20061239L NO 20061239 L NO20061239 L NO 20061239L NO 20061239 A NO20061239 A NO 20061239A NO 20061239 A NO20061239 A NO 20061239A NO 20061239 L NO20061239 L NO 20061239L
Authority
NO
Norway
Prior art keywords
reagents
treatment
methods
inflammatory disorders
immune inflammatory
Prior art date
Application number
NO20061239A
Other languages
English (en)
Inventor
Edward Roydon Jost-Price
Brendan Smith
Benjamin A Auspitz
Bradley B Brasher
Noah Sachs
Todd W Chappell
Palaniyandi Manivasakam
Michael S Slavonic
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of NO20061239L publication Critical patent/NO20061239L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oppfinnelsen angår en metode for behandling av en pasient diagnostisert med eller med risiko for å utvikle, en immunoinflammatorisk lidelse ved administrering til pasienten av et antihistamin, enten alene eller i kombinasjon med ett eller flere ytterligere midler. Oppfinnelsen angår også et farmasøytisk preparat inneholdende et antihistamin i kombinasjon med ett eller flere ytterligere midler.
NO20061239A 2003-09-15 2006-03-17 Fremgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser NO20061239L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50302603P 2003-09-15 2003-09-15
PCT/US2004/030210 WO2005027839A2 (en) 2003-09-15 2004-09-15 Methods and reagents for the treatment of immunoinflammatory disorders

Publications (1)

Publication Number Publication Date
NO20061239L true NO20061239L (no) 2006-06-08

Family

ID=34375301

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061239A NO20061239L (no) 2003-09-15 2006-03-17 Fremgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser

Country Status (18)

Country Link
US (1) US20050192261A1 (no)
EP (1) EP1670427A4 (no)
JP (1) JP2007516217A (no)
KR (1) KR20060089725A (no)
CN (1) CN101102760A (no)
AR (1) AR047841A1 (no)
AU (1) AU2004273880A1 (no)
BR (1) BRPI0414435A (no)
CA (1) CA2537989A1 (no)
IL (1) IL174185A0 (no)
IS (1) IS8410A (no)
MX (1) MXPA06002929A (no)
NO (1) NO20061239L (no)
RU (1) RU2006112587A (no)
SG (1) SG146653A1 (no)
TW (1) TW200522932A (no)
WO (1) WO2005027839A2 (no)
ZA (1) ZA200601973B (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6765001B2 (en) 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
TW200902047A (en) * 2003-02-14 2009-01-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
ATE497763T1 (de) 2003-11-21 2011-02-15 Zalicus Inc Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
LT2522365T (lt) 2004-11-24 2017-02-10 Meda Pharmaceuticals Inc. Kompozicijos, apimančios azelastiną, ir jų panaudojimo būdai
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
AU2005314133B2 (en) 2004-12-06 2012-03-08 Medicinova, Inc. Ibudilast for treating neuropathic pain and associated syndromes
DE602006015387D1 (de) 2005-04-13 2010-08-26 Astion Dev As Beta-2 Adrenoceptor Agonisten zur Behandlung von Bindegewebserkrankungen der Haut
DK1874821T3 (da) 2005-04-26 2013-07-08 Trion Pharma Gmbh Kombination af antistoffer med glykokortikoider til behandling af kræft
EP1919450B1 (en) * 2005-09-01 2014-06-11 Meda AB Antihistamine- and corticosteroid-containing liposome composition and its use for the manufacture of a medicament for treating rhinitis and related disorders
JP2009514969A (ja) * 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
US20070179121A1 (en) * 2006-02-02 2007-08-02 Plott R T Method of treating pediatric patients with corticosteroids
CA2644421A1 (en) * 2006-03-07 2007-09-13 Vertex Pharmaceuticals Incorporated Use of vx-702 for treating rheumatoid arthritis
AU2007258567B2 (en) * 2006-06-06 2012-04-19 Medicinova, Inc. Substituted pyrazolo (1,5-alpha) pyridine compounds and their methods of use
US9205080B2 (en) * 2006-11-16 2015-12-08 Transderm, Inc. Methods of treating keratin hyperproliferation disorders using mTOR inhibitors
GB0701171D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
KR20100014565A (ko) * 2007-04-11 2010-02-10 알콘 리서치, 리미티드 알레르기성 비염 및 알레르기성 결막염을 치료하기 위한 ｔｎｆａ의 억제제 및 항히스타민의 용도
US7536799B2 (en) * 2007-06-07 2009-05-26 Keson Industries Chalk line apparatus with strategically located chalk fill opening
JP5715820B2 (ja) * 2007-09-18 2015-05-13 スタンフォード ユニバーシティー フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物
US9101628B2 (en) * 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
US9149463B2 (en) * 2007-09-18 2015-10-06 The Board Of Trustees Of The Leland Standford Junior University Methods and compositions of treating a Flaviviridae family viral infection
US8940730B2 (en) 2007-09-18 2015-01-27 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a Flaviviridae family viral infection
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010048264A2 (en) * 2008-10-23 2010-04-29 Combinatorx, Incorporated Methods and compositions for the treatment of immunoinflammatory disorders
CN102448458B (zh) * 2009-03-18 2015-07-22 小利兰·斯坦福大学理事会 治疗黄病毒科病毒感染的方法和组合物
EA016240B1 (ru) * 2009-10-13 2012-03-30 Федеральное Государственное Учреждение "Государственный Научный Центр Дерматовенерологии Федерального Агентства По Высокотехнологичной Медицинской Помощи" Способ прогнозирования эффективности лечения больных псориазом инфликсимабом
GB201121812D0 (en) 2011-12-07 2012-02-01 Teva Branded Pharmaceutical Prod R & D Inc NAsal formulation
EP2705847B1 (en) * 2012-09-05 2014-07-02 PSoriasis+Creams Sweden AB Composition for treating psoriasis
CN103830731A (zh) * 2012-11-26 2014-06-04 天津金耀集团有限公司 糖皮质激素与h1受体拮抗剂的复方吸入组合物
CN103830208A (zh) * 2012-11-26 2014-06-04 天津金耀集团有限公司 含有h1受体拮抗剂的吸入制剂
CN103830730A (zh) * 2012-11-26 2014-06-04 天津金耀集团有限公司 布地奈德与h1受体拮抗剂的复方吸入药物
CN103830728A (zh) * 2012-11-26 2014-06-04 天津金耀集团有限公司 环索奈德与h1受体拮抗剂的复方吸入药物
BR102012030828A2 (pt) 2012-12-03 2014-09-16 Ems Sa Composição farmacêutica compreendendo desloratadina e prednisolona e seu uso
US9370527B2 (en) 2012-12-28 2016-06-21 The Regents Of The University Of Michigan Amelioration of intestinal fibrosis and treatment of Crohn's disease
EP2948134B1 (en) 2013-01-24 2020-03-04 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mtor inhibitors
SG11201704640SA (en) * 2015-01-12 2017-07-28 Agency Science Tech & Res Monoclonal antibody against muramyl peptides in prevention and treatment of immune-mediated diseases
CN104940179B (zh) * 2015-05-29 2017-10-27 中国人民解放军第二军医大学 盐酸苯海拉明在制备治疗实验性自身免疫性脑脊髓炎药物中的应用
NZ776616A (en) * 2015-06-30 2024-11-29 Eiger Group Int Inc Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
RU2627424C1 (ru) * 2016-11-03 2017-08-08 Лонг Шенг Фарма Лимитед Фармацевтический препарат для лечения ревматологических заболеваний
IL267869B2 (en) 2017-01-06 2023-10-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
US10765630B2 (en) * 2018-03-16 2020-09-08 SEN-JAM Pharmaceutical LLC Methods and compositions to treat enteropathic arthritis
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
EP4236949A4 (en) * 2020-10-30 2024-09-25 The Board of Trustees of the Leland Stanford Junior University DRUGS TARGETING INFLAMMATION FOR THE TREATMENT OF OSTEOARTHRITIS AND OTHER INFLAMMATORY DISEASES
CN118903128B (zh) * 2024-08-07 2025-03-25 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 阿司咪唑在制备治疗Tfh相关自身免疫性疾病药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3231468A (en) * 1962-07-02 1966-01-25 Merck & Co Inc Dexamethasone-cyproheptadine oral antiflammatory compositions
US3419655A (en) * 1967-03-17 1968-12-31 American Home Prod Treatment of inflammations by administering a cycloleucyl compound
US4444780A (en) * 1982-08-30 1984-04-24 Ortho Pharmaceutical Corporation Method for treating atopic dermatitis
US5166149A (en) * 1989-09-08 1992-11-24 Chemex Pharmaceuticals, Inc. Methotrexate compositions and methods of treatment using same
US5030634A (en) * 1990-03-29 1991-07-09 Krumdieck Carlos L 10-deazaaminopterin: a new arthritis remittive drug
AU710339B2 (en) * 1994-10-05 1999-09-16 Amarin Neuroscience Limited Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound
AU4472396A (en) * 1994-12-30 1996-07-24 American Home Products Corporation Clear non-alcoholic hydrocortisone solutions
US5736537A (en) * 1995-09-12 1998-04-07 Estee Lauder, Inc. Dehydroep:androsterone sailcylate useful against skin atrophy
EP0780127A1 (en) * 1995-12-19 1997-06-25 The Procter & Gamble Company A nasal spray containing a steroid and a antihistamine
AU3153797A (en) * 1996-06-04 1998-01-05 Procter & Gamble Company, The A nasal spray containing an intranasal steroid and an antihistamine
IN188720B (no) * 1997-11-06 2002-11-02 Panacea Biotec Ltd
US6140337A (en) * 1997-12-23 2000-10-31 Schering Corporation Methods for the treatment of mental disorders
US6423721B1 (en) * 1998-09-10 2002-07-23 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
AU3126700A (en) * 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
JP2001510485A (ja) * 1999-03-01 2001-07-31 シェーリング コーポレイション アトピー性皮膚炎、血管性浮腫および他の障害を抗ヒスタミン薬およびグルココルチコイドを用いて処置するための組成物および方法
GB0023220D0 (en) * 2000-09-21 2000-11-01 Arakis Ltd Corticosteroid formulation
US20020006961A1 (en) * 1999-05-14 2002-01-17 Katz Stanley E. Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
ES2284531T3 (es) * 1999-10-08 2007-11-16 Schering Corporation Tratamiento nasal topico usando desloratadina y furoato de mometasona.
EP1267870A2 (en) * 2000-04-07 2003-01-02 Schering Corporation Inhibition of cytokine generation
US6488937B1 (en) * 2000-08-23 2002-12-03 William Smits Allergy treatment method using a rapid immunotherapy protocol
JP4269144B2 (ja) * 2000-10-02 2009-05-27 エモリー ユニバーシティ 自己免疫疾患および炎症障害の処置のためのトリプトリドアナログ
US6599914B2 (en) * 2001-04-24 2003-07-29 Schering Corporation Inhibition of cytokine generation
US7034059B2 (en) * 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
WO2003020274A1 (en) * 2001-08-30 2003-03-13 Aventis Pharmaceuticals Inc. Treatment of atopic dermatitis
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
TW200902047A (en) * 2003-02-14 2009-01-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

Also Published As

Publication number Publication date
AU2004273880A1 (en) 2005-03-31
MXPA06002929A (es) 2006-06-14
JP2007516217A (ja) 2007-06-21
ZA200601973B (en) 2008-08-27
CN101102760A (zh) 2008-01-09
EP1670427A2 (en) 2006-06-21
BRPI0414435A (pt) 2006-11-14
KR20060089725A (ko) 2006-08-09
WO2005027839A2 (en) 2005-03-31
CA2537989A1 (en) 2005-03-31
IL174185A0 (en) 2006-08-01
TW200522932A (en) 2005-07-16
US20050192261A1 (en) 2005-09-01
AR047841A1 (es) 2006-03-01
IS8410A (is) 2006-04-12
WO2005027839A3 (en) 2007-06-28
RU2006112587A (ru) 2007-10-27
EP1670427A4 (en) 2009-01-07
SG146653A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
NO20061239L (no) Fremgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser
NO20062003L (no) Fremgangsmate og forbindelser for behandling av immunoinflammatoriske forstyrrelser
Walker et al. Leucine competes with kynurenine for blood-to-brain transport and prevents lipopolysaccharide-induced depression-like behavior in mice
NO20053678L (no) Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser
AR046682A1 (es) Terapia de combinacion para tratamiento de desordenes neovasculares oculares
BR0308290A (pt) Tratamento e prevenção de distúrbios inflamatórios
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
NO20023473D0 (no) Sammensetninger for levering av en kortisol antagonist
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
WO2008118148A3 (en) Adiponectin for the treatment and diagnosis of albuminuria
WO2009073544A3 (en) Methods for treating a disorder by regulating gprc6a
CY1110620T1 (el) Μεθοδος θεραπειας οξειας παραρρινοκολπιτιδας
NO20062300L (no) Fremgangsmater og reagenser for behandling av inflammatoriske forstyrelser
NO20055907L (no) Fremgangsmate for behandling av en angstforstyrrelse
DE60336068D1 (de) Antikörper gerichtet gegen oxidierten Apolipoprotein B
NO20062363L (no) Fremgangsmater og reagenser for behandling av inflammatoriske forstyrrelser
BR0313588A (pt) Métodos para o tratamento da demência com base em apo e genótipo
BR0314713A (pt) Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
Shemer et al. Toenail abnormalities and onychomycosis in chronic venous insufficiency of the legs: should we treat?
Pešić et al. Molecular Mechanism and Clinical Relevance of Ketamine as Rapid‐Acting Antidepressant
WO2010048264A3 (en) Methods and compositions for the treatment of immunoinflammatory disorders
RU2001118082A (ru) Способ лечения заболеваний зрительного анализатора
WO2004100899A3 (en) Use of secretin in treatments of disorders associated with the amygdala

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application